The Impact of Blood Transfusion in Developing Postoperative Delirium in Patients with Hip Fracture Surgery
1
Department of Orthopedic Surgery, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon 24253, Republic of Korea
2
Division of Big Data and Artificial Intelligence, Institute of New Frontier Research, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon 24253, Republic of Korea
3
Department of Anesthesiology and Pain Medicine, College of Medicine, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon 24253, Republic of Korea
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
J. Clin. Med. 2023, 12(14), 4696; https://doi.org/10.3390/jcm12144696
Submission received: 27 May 2023
/
Revised: 11 July 2023
/
Accepted: 12 July 2023
/
Published: 14 July 2023
(This article belongs to the Section Orthopedics)
Abstract
:Background: Many studies have been conducted to explore the risk factors associated with postoperative delirium (POD) in order to understand its underlying causes and develop prevention strategies, especially for hip fracture surgery. However, the relationship between blood transfusion and POD has been heatedly debated. The purpose of this study was to evaluate the risk factors of POD and the relationship between blood transfusions and the occurrence of POD in hip fracture surgery through big data analysis. Methods: Medical data (including medication history, clinical and laboratory findings, and perioperative variables) were acquired from the clinical data warehouse (CDW) of the five hospitals of Hallym University Medical Center and were compared between patients without POD and with POD. Results: The occurrence of POD was 18.7% (228 of 2398 patients). The risk factors of POD included old age (OR 4.38, 95% CI 2.77–6.91; p < 0.001), American Society of Anesthesiology physical status > 2 (OR 1.84 95% CI 1.4–2.42; p < 0.001), dementia (OR 1.99, 95% CI 1.53–2.6; p < 0.001), steroid (OR 0.53 95% CI 0.34–0.82; p < 0.001), Antihistamine (OR 1.53 95% CI 1.19–1.96; p < 0.001), and postoperative erythrocyte sedimentation rate (mm/h) (OR 0.97 95% CI 0.97–0.98; p < 0.001) in multivariate logistic regression analysis. The postoperative transfusion (OR 2.53, 95% CI 1.88–3.41; p < 0.001) had a significant effect on the incidence of POD. Conclusions: big data analytics using a CDW was a good option to identify the risk factors of POD and to prevent POD in hip fracture surgery.
1. Introduction
Postoperative delirium (POD) is often a complication in patients with hip fracture surgery [1]. The occurrence of POD after hip fracture surgery varied from 9 to 42% [2]. POD is involved with a long hospital stay, higher financial costs, increased morbidity, and mortality [3]. In previous studies, several strategies (including the identification of risk factors for POD) have been studied to identify the pathogenesis of POD and prevent POD in hip fracture surgery [4,5,6]. However, the pathogenesis remains controversial. One of the mechanisms is a deficit in brain perfusion, which is caused by hypotensive events in relation to intraoperative blood loss [7,8]. Therefore, blood transfusion can be associated with the development of POD after hip fracture surgery [9,10]. Multiple studies have investigated the relationship between blood transfusion and POD in hip fracture surgery. Some studies have reported a positive relationship between blood transfusion and POD [3,11,12], while other studies have reported inconsistent findings (no relationship) [13,14].
Recently, big data analysis using a clinical data warehouse (CDW) has been used in medical research. This has made it possible to analyze structured and unstructured data quickly and precisely [15]. Hence, we applied big data analysis using a CDW to evaluate the incidence and risk factors of POD quickly and precisely.
Therefore, the purpose of this study was to identify the risk factors of POD and evaluate the relationship between blood transfusions and the occurrence of POD in hip fracture surgery through big data analysis.
2. Materials and Methods
2.1. Ethics and Data
This study is a retrospective study and was performed after achieving approval from the Clinical Research Ethics Committee of Hallym University Chuncheon Sacred Heart Hospital. Although this study included vulnerable participants such as the elderly, informed consent was waived for all subjects because patients had already completed their treatment, and this was a historical cohort analysis of the clinical data obtained from the completed course of treatment.
All data were obtained from the CDW of Hallym University Medical Center. CDW included clinical data from 5 hospitals of Hallym University Medical Center, and the clinical data included an integrated database of outpatient and inpatient medical records, prescriptions, and laboratory and imaging tests.
2.2. Participants
The participants were patients >18 years of age who underwent hip surgery due to the fracture of their hip joint from January 2011 to July 2022. Exclusion criteria were as follows: patients had delirium before surgery, patients underwent ventilator treatment after surgery, patients experienced a lack of consciousness after surgery, patients underwent other surgery simultaneously, patients underwent sedation therapy after surgery, and patients had missing data.
2.3. Exposure Variables and Primary Outcomes
The exposure variable included the intraoperative transfusion amount of red blood cells (RBC) and the transfusion of RBC during observation periods after surgery. Pack and Pack/day were used as the unit for the intraoperative transfusion and postoperative transfusion, respectively. The occurrence of POD was evaluated for 7 days after surgery. The short-form Korean Nursing Delirium Screening Scale was used for the diagnosis of POD. Once patients were suspected to be POD through the short-form Korean Nursing Delirium Screening Scale, the patients were referred for psychiatric counseling, and the diagnosis of POD was confirmed. The occurrence of POD was defined as patients with words indicating the specific symptoms and signs of delirium in postoperative psychiatric counseling notes. The list of words indicating specific symptoms and signs of delirium was predetermined in a previous study (Appendix A) [16]. Additionally, the odds ratios of perioperative risk factors, including intra- and postoperative red blood cell transfusion, were calculated.
2.4. Preoperative Factors
The preoperative risk factors were: age, male, obesity (body mass index >29.9), an American society of Anesthesiology physical status > 2, emergency surgery, preoperative morbidities(hypertension, diabetes, stroke, cancer, Parkinson disease, dementia, depression, kidney disease, liver disease, insomnia), medication (calcium channel blocker, diuretics, beta blocker, angiotensin converting enzyme inhibitors, angiotensin-receptor blockers, miscellaneous drug antidepressants, hypnotics, anti-psychotics, opioid, non-steroidal anti-inflammatory drug, analgesic except non-steroidal anti-inflammatory drug, muscle relaxants, steroid, anti-platelet, anti-coagulants, anti-hyperlipidemic, anti-Parkinson, antihistamine, genitourinary drug, h2-blocker), alcohol, smoking, and a laboratory test (hemoglobin [≥10, 9.9–8, 7.9–6, <6 g/dL], aspartate aminotransferase [difference from upper normal level], alanine aminotransferase [difference from upper normal level], sodium [hyponatremia, normal level, hypernatremia], potassium [hypokalemia, normal range, hyperkalemia], uric acid [difference from upper normal range], blood urea nitrogen [difference from upper normal range], creatinine [difference from upper normal range], albumin [hypoalbuminemia, normal level, hyperalbuminemia]). The list of drugs was created in a previous study (Appendix B) [16].
2.5. Intraoperative Factors
Intraoperative risk factors included the surgical type (open reduction and internal fixation, hip hemiarthroplasty, and total hip arthroplasty), operation time, the use of propofol as maintenance anesthetics, the use of opioids, amounts of midazolam (mg), oliguria (<0.5 mL/kg/h), administered fluid amounts (L), estimated blood loss (L), and the transfusion amount(pack).
2.6. Postoperative Factors
Postoperative risk factors included the transfusion amount, laboratory test (hemoglobin, sodium, potassium, uric acid, blood urea nitrogen, creatinine, albumin, aspartate aminotransferase, alanine aminotransferase, C-reactive protein, erythrocyte sedimentation rate), maximum body temperature, intensive care unit admission, and patient-controlled analgesia. Postoperative laboratory test results were expressed as the same method as preoperative laboratory tests.
2.7. Statistics
The statistical analysis was performed by IBM SPSS Statistics (version 26.0; IBM Corp., Armonk, NY, USA). Continuous data were described as median, interquartile ranges (IQRs), and maximum values, while categorical data were described as frequencies and percentages. Continuous data were analyzed by the Mann–Whitney test or independent t-test, and categorical data were analyzed by the chi-square test. The unadjusted and adjusted odds ratio and 95% confidence intervals were calculated to develop POD using Multivariate Coxregression. Statistical significance (p-value < 0.05) was considered.
3. Results
From January 2011 to July 2022, 6984 patients underwent hip surgery due to hip fractures at one of the five hospitals of Hallym University. In total, 4586 patients were excluded. Thus, 2398 patients were initially included in this study. The flow chart is summarized in Figure 1.
After surgery, 448 (18.7%) patients developed POD within 7 days. The preoperative, intraoperative, and postoperative risk factors of patients are summarized in Table 1.
Intraoperative red blood cell transfusions were performed for 226 (50.4%) of the patients who experienced POD and 810 (41.5%) of the patients without POD. Postoperative red blood cell transfusions were performed for 158 (35.3%) of the patients who experienced POD and 878 (45.0%) of the patients without POD. The red blood cell transfusion distributions are summarized in Table 2.
4. Discussion
Anemia has been known to be a risk factor for POD after hip fracture surgery [11,13]. Preoperative anemia is common in patients with hip fractures due to fracture site bone bleeding. The occurrence of preoperative anemia was higher than 60% in patients with a hip fracture. Prolonged hypotension could lead to low cerebral perfusion, cerebral ischemia, hypoxia, and the impairment of brain function [17,18]. In recent years, a newmonitoring tool using artificial intelligence has been developed, which can predict episodes of intraoperative hypotension and prevent prolonged hypotension [19,20]. Perioperative blood loss can also lead to decreased cerebral blood flow (cerebral ischemia, hypoxia, impairment of brain function), impaired metabolism, and inflammatory reactions [17]. The impairment of oxygen delivery caused by low cerebral perfusion could cause POD [18]. If large blood losses lead to unstable vital signs in patients, a red blood cell transfusion is conducted. Therefore, red blood cell transfusion due to perioperative blood loss is highly associated with POD. Several investigators have explored the association between red blood cell transfusion and POD after hip fracture surgery; however, these results are controversial. Some studies have reported a positive association between red blood cell transfusion and POD [21,22,23], while others have found no association [14,24]. In this study, there was no relationship between the pre-, intra-, and postoperative hemoglobin level (anemia) with red blood cell transfusion and the incidence of POD after hip fracture surgery. However, postoperative red blood cell transfusion has also been associated with developing POD. These findings suggest that the perioperative hemoglobin level is not related to POD. Therefore, red blood cell transfusion-related complications (like increased inflammation and oxidative stress) might contribute to the occurrence of POD [25,26]. One unit of the red blood cell has a million donor leukocytes and proteins. Allogenic leukocytes or proteins could enhance inflammation and injure immunity. In a recent study, an older red blood cell transfusion was associated with increased neuro-inflammation and the increased duration of delirium [27,28]. The optimal transfusion trigger in orthopedic surgical patients recommends maintaining a hemoglobin level of >8.0 g/dL [14]. However, some studies compared red blood cell transfusion (to maintain a hemoglobin level of >8.0 g/dL) with restrictive red blood cell transfusion (to maintain a hemoglobin level of >7.0 g/dL). A restrictive red blood cell transfusion significantly decreased cardiac morbidity and readmission in hip fracture surgery [29]. Therefore, a restrictive red blood cell transfusion has been recommended to prevent POD in hip fracture surgery.
The occurrence of POD after hip fracture surgery varied between 12% and 51% [9,30]. In this study, the occurrence of POD was 18.7%. The differences between diagnostic methods, surgery procedures, and anesthesia could lead to a variety in the occurrence of POD [21,31,32].
POD is a serious complication after surgery in patients. POD has been shown to delay recovery and prolong hospital stays [33,34]. Therefore, the identification of the risk factors for POD is the first step to clarifying the pathogenesis of POD and preventing POD [30,35]. In this study, the risk factors of POD were identified in hip fracture surgery through a complete evaluation using big data. Old age, American Society of Anesthesiologists physical status >2, dementia, antihistamine, steroid, erythrocyte sedimentation rate(mm/h), and postoperative red blood cell transfusion were significantly associated with POD (Table 4).
Previous studies have shown that the higher occurrence of POD in old age could be related to increased comorbidities as well as impaired physiologic compensatory capability to adjust surgical stress [30]. In addition, the changes in the content of central neurotransmitters (such as acetylcholine, norepinephrine, epinephrine, etc.) were associated with POD in advanced age [22].
Some studies have reported that the type of anesthesia is a significant risk factor for POD [23]. Additionally, inconsistent findings have been reported [36,37]. In this study, there was no significant difference in the type of anesthesia between patients with POD and those without POD.
Several studies have shown that ASA status is linked to poor general conditions and multiple comorbidities [38]. Additionally, ASA classification (>2 levels) was associated with POD after hip fracture surgery in this study.
Generally, polypharmacy, medications with anti-psychotics, and anticholinergic activity have been associated with POD [24]. All drugs were investigated. In this study, the administration of antihistamines could be related to the higher incidence of POD. On the other hand, the administration of the steroid could be related to the lower incidence of POD.
Emergency surgery makes patients feel uncomfortable. Emergency surgery has been related to the occurrence of POD [39]. However, other studies reported a higher occurrence of POD in non-emergency surgeries [40]. In this study, there was no significant relationship between emergency surgery and POD.
This study has some limitations. The short-form Korean Nursing Delirium Screening Scale was used for the diagnosis of POD. Once patients were suspected to have POD through the short-form Korean Nursing Delirium Screening Scale, the patients were referred to psychiatric counseling, and the diagnosis of POD was confirmed. Therefore, patients who had mild symptoms of POD and did not receive treatment by psychiatrists could have been excluded. The exclusion of these patients might have affected the accuracy of the diagnosis of POD and the analysis of the association among risk factors.
Another limitation was that the occurrence of POD was evaluated 7 days after hip fracture surgery. Patients who developed POD after discharge were not included. The exclusion of these patients could introduce selection bias and limit the representativeness of the sample.
All confounding factors influencing the relationship between blood transfusion and POD could not be adjusted due to the observational nature of this study. This could have affected the accuracy of the causality evaluation. Finally, data were retrospectively analyzed. Therefore, the brain imaging study was not evaluated in all patients. The severity of POD and cognitive dysfunction could not be analyzed.
5. Conclusions
In this study, CDW was used for the evaluation of risk factors of POD. The occurrence of POD after hip fracture surgery was 18.7%. There was no relationship between perioperative anemia and red blood cell transfusion and the occurrence of POD in hip fracture surgery. However, postoperative red blood cell transfusion was associated with the development of POD. Therefore, red blood cell transfusion in relation to complications (like increased inflammation and oxidative stress) contributes to the occurrence of POD. Big data analytics using CDW is a good option to identify the risk factors of POD and to prevent POD in hip fracture surgery.
Author Contributions
Conceptualization, S.-S.L., Y.-S.K., J.-H.K., J.-J.L. and E.-M.S.; methodology, S.-S.L., Y.-S.K., J.-H.K., J.-J.L. and E.-M.S.; validation, Y.-S.K. and J.-H.K.; formal analysis, Y.-S.K. and J.-H.K.; investigation, S.-S.L., Y.-S.K., J.-H.K., J.-J.L. and E.-M.S.; data curation, Y.-S.K. and J.-H.K.; writing—original draft preparation, E.-M.S.; writing—review and editing, S.-S.L., Y.-S.K., J.-H.K., J.-J.L. and E.-M.S.; supervision, Y.-S.K. and E.-M.S. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
Ethical approval for this study (2022-09-005) was provided by the Clinical Research Ethics Committee of Chuncheon Sacred Heart Hospital, Hallym University, Chuncheon, Republic of Korea.
Informed Consent Statement
Despite the inclusion of vulnerable participants because this study used a historical cohort analysis of clinical data, which was acquired during an already completed treatment processes, informed consent was waived for all subjects.
Data Availability Statement
All data were obtained from the clinical data warehouse (CDW) of the five hospitals of Hallym University Medical Center.
Conflicts of Interest
The authors declare no conflict of interest.
Appendix A. Predetermined Word List Describing Delirium
| Actual Investigated Words | Translation in English |
| delirium | delirium |
| confusion | confusion |
| psychosis | psychosis |
| violent | violent |
| vigilant | vigilant |
| hyper alert | hyper alert |
| attention | attention |
| irritable | irritable |
| attentional deficit | attentional deficit |
| fluctuation | fluctuation |
| 섬망 | delirium |
| 헛소리 | gibberish, delirious talking |
| 헛것 | visual hallucination |
| 지른다 | yell |
| 환시 | visual hallucination |
| 환청 | auditory hallucination |
| 환각 | hallucination |
| 망상 | delusion |
| 의식변화 | altered mentality |
| 의식혼탁 | clouding of consciousness |
| 집중력 | concentration |
| 외부자극 | external stimuli |
| 외부반응 | response to a stimulus |
| 반응성 | response |
| 이상행동 | abnormal behavior |
| 과다행동 | hyperactive |
| 행동변화 | behavioral changes |
| 공격 | aggression |
| 난폭 | violence |
| 충동적 | impulsive |
| 돌발행동 | unexpected behavior |
| 집중력 | concentration |
| 주의산만 | distraction |
| 횡설수설 | gibberish |
| 안절부절 | restlessness |
| 불안 | restlessness |
| 엉뚱 | absurd |
| 비논리적 | irrational |
| 상관없는 | unconnected |
| 각성 | alertness |
| 무기력 | lethargy |
| 인지능력 | cognitive function |
| 초조 | restlessness |
| 흥분 | agitation |
| 혼미 | confusion |
| 혼돈 | confusion |
| 혼란 | confusion |
| 지남력 | orientation |
| 불면 | insomnia |
| 요실금 | urinary incontinence |
| 졸림 | drowsy |
| 배회 | wandering |
| 혼잣말 | self-talking |
| 욕설 | swear |
| 고함 | yell |
Appendix B. Drugs of Medication Factors
| Pharmacologic Category | Drug |
| CCBs | Amlodipine, Barnidipine, Benidipine, Cilnidipine, Diltiazem, Efonidipine, Felodipine, Lacidipine, Lercanidipine Manidipine, Nicardipine, Nifedipine, Verapamil |
| Diuretics | Acetazolamide, Amiloride, Furosemide, hydrochlorothiazide, D-mannitol, Indapamide, Isosorbide, Spironolactone, Torasemide |
| Beta blockers | Arotinolol, Atenolol, Bisoprolol, Carvedilol, Labetalol, Metoprolol, Nebivolol, Propranolol |
| ACE inhibitors | Captopril, Cilazapril, Enalapril, Fosinopril Perindopril, Ramipril |
| ARBs | Candesartan, Eprosartan, Fimasartan Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan |
| Other antihypertensives | Amlodipine/Losartan, Ambrisentan, Bisoprolo/Hydrochlorothiazide, Bosentan. Candesartan/ Hydrochlorothiazide, Eprosartan/Hydrochlorothiazide, Felodipin/Ramipril, Fimasartan/Hydrochlorothiazide, Irbesartan/Hydrochlorothiazide, Lercanidipine/Valsartan, Losartan /Hydrochlorothiazide, Amlodipine/Olmesartan/Hydrochlorothiazide, Amlodipine/Olmesartan, Olmesartan/Hydrochlorothiazide, Sildenafil, Amlodipine/Telmisartan, Telmisartan/ Hydrochlorothiazide, Amlodipine/Valsartan, Valsartan/ Hydrochlorothiazide |
| Miscellaneous CV drugs | Amlodipine/Atorvastatin, Irbesartan/Atorvastatin, Ulinastatin, Ivabradine, Olmesartan/Rosuvastatin, Omega-3 acid ethyl esters, Telmisartan/Rosuvastatin, Trimetazidine, Pitavastatin/Valsartan |
| Antidepressants | Amitriptyline, Amoxapine, Doxepin, Imipramine, nortriptyline, Tianeptine, Fluvoxamine, Paroxetine, Escitalopram, Sertraline, Vortioxetine, Bupropion, Mirtazapine, Trazodone, Duloxetine, Desvenlafaxine, Milnacipran, Venlafaxine |
| Hypnotics & sedatives | Alprazolam, Buspirone, Chlordiazepoxide, Chlordiazepoxide/Clidinium, Clobazam Chloral, Diazepam, Etizolam, Flurazepam, Dexmedetomidine, Lorazepam, Midazolam, Phenobarbital, Melatonin, Tandospirone, Triazolam, Zolpidem |
| Antipsychotics | Amisulpride, Aripiprazole, Blonanserin, Clozapine, Chlorpromazine, Haloperidol, Paliperidone, Risperidone, Olanzapine, Paliperidone, Quetiapine, Sulpiride, Ziprasidone |
| CNS stimulants | Atomoxetine, Clonidine, Modafinil, Methylphenidate |
| Antimanic agents | Lithium |
| Opioids | Buprenorphine, Fentanyl, Morphine, Oxycodone, Pethidine Sufentanil, Hydromorphone, Oxycodone, |
| Other analgesics (no NSAIDs) | Acetaminophen, Capsaicin, Ethanol, Nefopam, Propacetamol, Tramadol |
| NSAIDs | Aceclofenac, Celecoxib, Dexibuprofen, Diclofenac, Etoricoxib, Ibuprofen, Imidazole salicylate, Indomethacin, Ketoprofen, Ketorolac, Loxoprofen, Meloxicam, Nabumetone, Naproxen, Pelubiprofen, Polmacoxib, Zaltoprofen |
| Skeletal muscle relaxants | Afloqualone, Baclofen, Cyclobenzaprine, Dantrolene, Eperisone, Clostridium botulinum A toxin, Cisatracurium, Gallamine, Rocuronium, Suxamethonium, Vecuronium, Orphenadrine, Chlorphenesin, Thiocolchicoside, Aescin, Tizanidine |
| Corticosteroids | Budesonide, Deflazacort, Dexamethasone, Fludrocortisone, Hydrocortisone, Methylprednisolone, Triamcinolon, Prednisolone |
| Antiplatelet agents | Aspirin, Cilostazol, Cilostazol/Ginkgo Biloba Leaf Extract, Clopidogrel, Clopidogrel/Aspirin, Abciximab, Prasugrel, Sulodexide, Ticlopidine, Ticagrelor, Triflusal |
| Anticoagulants | Human AntithrombinⅢ, Enoxaparin, Gabexate, Heparin, Tirofiban, Warfarin, Tinzaparin, Apixaban, Dabigatran, Edoxaban, Argatroban, Rivaroxaban |
| Antihyperlipidemic agents | Atorvastatin/Ezetimibe, Atorvastatin, Cholestyramine, Ezetimibe, Fenofibric acid, Fluvastatin, Gemfibrozil, Lovastatin, Pitavastatin, Pravastatin/Fenofibrate, Rosuvastatin, Rosuvastatin/Ezetimibe, Simvastatin/ Ezetimibe, Simvastatin/Fenofibrate, Simvastatin |
| Antiparkinsonian agents | Amantadine, Levodopa/Benserazide, Bromocryptine, Benztropine, Levodopa/Carbidopa/Entacapone, Levodopa/Carbidopa, Entacapone, Pramipexole, Procyclidine, Rasagiline, Ropinirole, Selegiline, Trihexyphenidyl |
| Antihistamines/antiallergics | Azelastine, Levocetirizine, Chlorpheniramin, Dimenhydrinate, Desloratadine, Ebastine, Pseudoephedrine, Emedastine, Epinastine, Fexofenadine, γ-Linolenic acid, Hydroxyzine, Chlorpheniramine, Human IgG/Histamine, Ketotifen, Purified House Dust Mite allergen extract, Loratadine, Mequitazine, Olopatadine, Allergen extracts, Tranilast |
| Antivertigos | Betahistine, Cinnarizine/Dimenhydrinate |
| Genitourinary Smooth Muscle Relaxants | Fesoterodine, Atosiban, Mirabegron, Oxybutynin, Propiverine, Solifenacin, Trospium |
| H2 receptor antagonist | Cimetidine, Famotidine, Lafutidine, Nizatidine, Ranitidine |
| CCBs, Calcium channel blockers; ACE inhibitors: Angiotensin Converting Enzyme Inhibitors; ARBs, Angiotension II Receptor Blockers; CV, cardiovascular; NSAIDs, non-steroidal anti-inflammatory drugs. | |
References
- Chrispal, A.; Mathews, K.P.; Surekha, V. Clinical profile and association of delirium in geriatric patients with hip fractures in a tertiary care hospital in India. J. Assoc. Physicians India 2010, 58, 15–19. [Google Scholar]
- Siddiqi, N.; House, A.O.; Holmes, J.D. Occurrence and outcome of delirium in medical in-patients: A systematic literature review. Age Ageing. 2006, 35, 350–364. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Guo, Y.; Jia, P.; Zhang, J.; Wang, X.; Jiang, H.; Jiang, W. Prevalence and risk factors of postoperative delirium in elderly hip fracture patients. J. Int. Med. Res. 2016, 44, 317–327. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Janssen, T.L.; Alberts, A.R.; Hooft, L.; Mattace-Raso, F.; Mosk, C.A.; van der Laan, L. Prevention of postoperative delirium in elderly patients planned for elective surgery: Systematic review and meta-analysis. Clin. Interv. Aging 2019, 19, 1095–1117. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Aiello, G.; Cuocina, M.; Via, L.L.; Messina, S.; Attaguile, G.A.; Cantarella, G.; Sanfilippo, F.; Bernardini, R. Melatonin or Ramelteon for Delirium Prevention in the Intensive Care Unit: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J. Clin. Med. 2023, 12, 435. [Google Scholar] [CrossRef]
- Maldonado, J.R. Acute Brain Failure: Pathophysiology, Diagnosis, Management, and Sequelae of Delirium. Crit. Care Clin. 2017, 33, 461–519. [Google Scholar] [CrossRef]
- Smith, T.O.; Cooper, A.; Peryer, G.; Griffiths, R.; Fox, C.; Cross, J. Factors predicting incidence of post-operative delirium in older people following hip fracture surgery: A systematic review and meta-analysis. Int. J. Geriatr. Psychiatry 2017, 32, 386–396. [Google Scholar] [CrossRef] [Green Version]
- Wang, C.G.; Qin, Y.F.; Wan, X.; Song, L.C.; Li, Z.J.; Li, H. Incidence and risk factors of postoperative delirium in the elderly patients with hip fracture. J. Orthop. Surg. Res. 2018, 13, 186. [Google Scholar] [CrossRef] [Green Version]
- Fineberg, S.J.; Nandyala, S.V.; Marquez-Lara, A.; Oglesby, M.; Patel, A.A.; Singh, K. Incidence and risk factors for postoperative delirium after lumbar spine surgery. Spine 2013, 38, 1790–1796. [Google Scholar] [CrossRef]
- Musallam, K.M.; Tamim, H.M.; Richards, T.; Spahn, D.R.; Rosendaal, F.R.; Habbal, A.; Khreiss, M.; Dahdaleh, F.S.; Khavandi, K.; Sfeir, P.M.; et al. Preoperative an anemia and postoperative outcomes in non-cardiac surgery: A retrospective cohort study. Lancet 2011, 378, 1396–1407. [Google Scholar] [CrossRef]
- Behrends, M.; DePalma, G.; Sands, L.; Leung, J. Intraoperative blood transfusions are associated with early postoperative delirium in older patients. J. Am. Geriatr. Soc. 2013, 61, 365–370. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chou, M.Y.; Wang, Y.C.; Peng, L.N.; Liang, C.K.; Chu, C.S.; Liao, M.C.; Lin, Y.T.; Hsu, C.J.; Chen, L.K. Intraoperative blood transfusion predicts postoperative delirium among older patients undergoing elective orthopedic surgery: A prospective cohort study. Int. J. Geriatr. Psychiatry. 2019, 34, 881–888. [Google Scholar] [CrossRef] [PubMed]
- Van der Zanden, V.; Beishuizen, S.J.; Scholtens, R.M.; de Jonghe, A.; de Rooij, S.E.; van Munster, B.C. The effects of blood transfusion on delirium incidence. J. Am. Med. Dir. Assoc. 2016, 17, 748–753. [Google Scholar] [CrossRef] [PubMed]
- Zhu, C.; Yin, J.; Wang, B.; Xue, Q.; Gao, S.; Xing, L.; Wang, H.; Liu, W.; Liu, X. Restrictive versus liberal strategy for red blood-cell transfusion in hip fracture patients. Medicine 2019, 98, 32. [Google Scholar] [CrossRef]
- Kang, S.Y.; Seo, S.W.; Kim, J.Y. Comprehensive risk factor evaluation of postoperative delirium following major surgery: Clinical data warehouse analysis. Neurol. Sci. 2019, 40, 793–800. [Google Scholar] [CrossRef]
- Kwon, Y.S.; Kim, J.H.; Lee, J.J.; Seo, E.M. The Relationship between Perioperative Blood Transfusion and Postoperative Delirium in Patients Undergoing Spinal Fusion Surgery: Clinical Data Warehouse Analysis. Medicina 2022, 58, 268. [Google Scholar] [CrossRef]
- Simone, M.J.; Tan, Z.S. The role of inflammation in the pathogenesis of delirium and dementia in older adults: A review. CNS Neurosci. Ther. 2011, 17, 506–513. [Google Scholar] [CrossRef]
- Marcantonio, E.R.; Goldman, L.; Orav, E.J.; Cook, E.F.; Lee, T.H. The association of intraoperative factors with the development of postoperative delirium. Am. J. Med. 1998, 105, 380–384. [Google Scholar] [CrossRef]
- Schneck, E.; Schulte, D.; Habig, L.; Ruhrmann, S.; Edinger, F.; Markmann, M.; Habicher, M.; Rickert, M.; Koch, C.; Sander, M. Hypotension Prediction Index based protocolized haemodynamic management reduces the incidence and duration of intraoperative hypotension in primary total hip arthroplasty: A single centre feasibility randomised blinded prospective interventional trial. J. Clin. Monit. Comput. 2020, 34, 1149–1158. [Google Scholar] [CrossRef]
- Murabito, P.; Astuto, M.; Sanfilippo, F.; Via, L.L.; Vasile, F.; Basile, F.; Cappellani, A.; Longhitano, L.; Distefano, A.; Volti, G.L. Proactive Management of Intraoperative Hypotension Reduces Biomarkers of Organ Injury and Oxidative Stress during Elective Non-Cardiac Surgery: A Pilot Randomized Controlled Trial. J. Clin. Med. 2022, 11, 392. [Google Scholar] [CrossRef]
- Dasgupta, M.; Dumbrell, A.C. Preoperative risk assessment for delirium after noncardiac surgery: A systematic review. J. Am. Geriatr. Soc. 2006, 54, 1578–1589. [Google Scholar] [CrossRef]
- Qiu, Y.; Huang, X.; Huang, L.; Tang, L.; Jiang, J.; Chen, L.; Li, S. 5-HT(1A) receptor antagonist improves behavior performance of delirium rats through inhibiting PI3K/Akt/mTOR activation-induced NLRP3 activity. IUBMB Life 2016, 68, 311–319. [Google Scholar] [CrossRef] [PubMed]
- Huang, J.; Bin AbdRazak, H.R.; Yeo, S.J. Incidence of postoperative delirium in patients undergoing total knee arthroplasty-an Asian perspective. Ann. Transl. Med. 2017, 5, 321. [Google Scholar] [CrossRef] [Green Version]
- Bilotta, F.; Lauretta, M.P.; Borozdina, A.; Mizikov, V.M.; Rosa, G. Postoperative delirium: Risk factors, diagnosis and perioperative care. Minerva Anestesiol. 2013, 79, 1066–1076. [Google Scholar] [PubMed]
- Dodd, A.C.; Bulka, C.; Jahangir, A.; Mir, H.R.; Obremskey, W.T.; Sethi, M.K. Predictors of 30-day mortality following hip/pelvis fractures. Orthop. Traumatol. Surg. Res. 2016, 102, 707–710. [Google Scholar] [CrossRef] [PubMed]
- Maldonado, J.R. Neuropathogenesis of delirium: Review of current etiologic theories and common pathways. Am. J. Geriatr. Psychiatry 2013, 21, 1190–1222. [Google Scholar] [CrossRef]
- Tan, H.; Bi, J.; Wang, Y.; Zhang, J.; Zuo, Z. Transfusion of old RBCs induces neuroinflammation and cognitive impairment. Crit. Care Med. 2015, 43, e276–e286. [Google Scholar] [CrossRef] [Green Version]
- Zhang, Z.Y.; Gao, D.P.; Yang, J.J.; Sun, X.R.; Zhang, H.; Hu, J.; Fang, Z.Y.; Yang, J.J.; Ji, M.H. Impact of length of red blood cells transfusion on postoperative delirium in elderly patients undergoing hip fracture surgery: A cohort study. Injury 2016, 47, 408–412. [Google Scholar] [CrossRef]
- Amin, R.M.; DeMario, V.M.; Best, M.J.; Shafiq, B.; Hasenboehler, E.A.; Sterling, R.S.; Frank, S.M.; Khanuja, H.S. A restrictive hemoglobin transfusion threshold of less than 7 g/dL decreases blood utilization without compromising outcomes in patients with hip fractures. J. Am. Acad. Orthop. Surg. 2019, 27, 887–894. [Google Scholar] [CrossRef]
- Inouye, S.K.; Westendorp, R.G.; Saczynski, J.S. Delirium in elderly people. Lancet 2014, 383, 911–922. [Google Scholar] [CrossRef] [Green Version]
- Wong, C.L.; Holroyd-Leduc, J.; Simel, D.L.; Straus, S.E. Does this patient have delirium?: Value of bedside instruments. Jama 2010, 304, 779–786. [Google Scholar] [CrossRef] [PubMed]
- Bruce, A.J.; Ritchie, C.W.; Blizard, R.; Lai, R.; Raven, P. The incidence of delirium associated with orthopedic surgery: A meta-analytic review. Int. Psychogeriatr. 2007, 19, 197–214. [Google Scholar] [CrossRef] [PubMed]
- Brooks, P.B. Postoperative delirium in elderly patients. Am. J. Nurs. 2012, 112, 38–49. [Google Scholar] [CrossRef] [Green Version]
- Shi, C.; Yang, C.; Gao, R.; Yuan, W. Risk factors for delirium after spinal surgery: A meta-analysis. World Neurosurg. 2015, 84, 1466–1472. [Google Scholar] [CrossRef] [PubMed]
- Wu, C.H.; Chang, C.I.; Chen, C.Y. Overview of studies related to geriatric syndrome in Taiwan. J. Clin. Gerontol. Geriatr. 2012, 3, 14–20. [Google Scholar] [CrossRef] [Green Version]
- Wei, L.A.; Fearing, M.A.; Sternberg, E.J.; Inouye, S.K. The confusion assessment method: A systematic review of current usage. J. Am. Geriatr. Soc. 2008, 56, 823–830. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, W.Y.; Wu, W.L.; Gu, J.J.; Sun, Y.; Ye, X.F.; Qiu, W.J.; Su, C.Q.; Zhang, S.Q.; Ye, W.Q. Risk factors for postoperative delirium in patients after coronary artery bypass grafting: A prospective cohort study. J. Crit. Care 2015, 30, 606–612. [Google Scholar] [CrossRef]
- Alves, A.; Panis, Y.; Mantion, G.; Slim, K.; Kwiatkowski, F.; Vicaut, E. The AFC score: Validation of a 4-item predicting score of postoperative mortality after colorectal resection for cancer or diverticulitis: Results of a prospective multicenter study in 1049 patients. Ann. Surg. 2007, 246, 91–96. [Google Scholar] [CrossRef]
- Malik, A.T.; Quatman, C.E.; Phieffer, L.S.; Ly, T.V.; Khan, S.N. Incidence, risk factors and clinical impact of postoperative delirium following open reduction and internal fixation (ORIF) for hip fractures: An analysis of 7859 patients from the ACS-NSQIP hip fracture procedure targeted database. Eur. J. Orthop. Surg. Traumatol. 2019, 29, 435–446. [Google Scholar] [CrossRef]
- Gao, R.; Yang, Z.Z.; Li, M.; Shi, Z.C.; Fu, Q. Probable risk factors for postoperative delirium in patients undergoing spinal surgery. Eur. Spine J. 2008, 17, 1531–1537. [Google Scholar] [CrossRef] [Green Version]
Figure 1.
Flow chart.
Table 1.
Preoperative, intraoperative, and postoperative factors of patients.
| No Delirium (n = 1950) | Delirium (n = 448) | p-Value | |
|---|---|---|---|
| Preoperative factors | |||
| Age, year (median [IQR], maximum) | 76 ([65, 82], 99) | 82 ([76, 87], 103) | <0.001 |
| Male, n (%) | 651 (33.4) | 131 (29.2) | 0.092 |
| Obesity (Bodymassindex > 29.9), n (%) | 60 (3.1) | 4 (0.9) | 0.01 |
| ASA physical status >2, n (%) | 953 (48.9) | 350 (78.1) | <0.001 |
| Emergency surgery (n, %) | 449 (23.0) | 84 (18.8) | 0.05 |
| Hypertension, n (%) | 1067 (54.7) | 290 (64.7) | <0.001 |
| Diabetes, n (%) | 507 (26.0) | 133 (29.7) | 0.112 |
| Stroke, n (%) | 270 (13.8) | 80 (17.9) | 0.03 |
| Cancer, n (%) | 196 (10.1) | 55 (12.3) | 0.165 |
| Parkinson disease, n (%) | 49 (2.5) | 23 (5.1) | 0.003 |
| Dementia, n (%) | 113 (5.8) | 78 (17.4) | <0.001 |
| Depression, n (%) | 70 (3.6) | 19 (4.2) | 0.511 |
| Kidney disease, n (%) | 135 (6.9) | 33 (7.4) | 0.74 |
| Liver disease, n (%) | 89 (4.6) | 17 (3.8) | 0.475 |
| Insomnia, n (%) | 128 (6.6) | 40 (8.9) | 0.077 |
| Alcohol, n (%) | 355 (18.2) | 48 (10.7) | <0.001 |
| Smoking, n (%) | 249 (12.8) | 44 (9.8) | 0.086 |
| Calcium channel blocker, n (%) | 757 (38.8) | 199 (44.4) | 0.029 |
| Diuretics, n (%) | 212 (10.9) | 45 (10.0) | 0.61 |
| Beta blocker, n (%) | 171 (8.8) | 29 (6.5) | 0.113 |
| Angiotensin converting enzyme inhibitors, n (%) | 15 (0.8) | 5 (1.1) | 0.467 |
| Angiotensin receptor blockers, n (%) | 131 (6.7) | 32 (7.1) | 0.747 |
| Miscellaneous drug, n (%) | 201 (10.3) | 25 (5.6) | 0.002 |
| Anti-depressant, n (%) | 58 (3.0) | 8 (1.8) | 0.166 |
| Hypnotics, n (%) | 780 (40.0) | 146 (32.6) | 0.004 |
| Anti-psychotics, n (%) | 277 (14.2) | 65 (14.5) | 0.868 |
| Opioid, n (%) | 1921 (98.5) | 442 (98.7) | 0.814 |
| Non-steroid alanti-inflammatory drug, n (%) | 549 (28.2) | 93 (20.8) | 0.001 |
| Analgesic except non-steroid alanti-inflammatory drug, n (%) | 1884 (96.6) | 439 (98.0) | 0.131 |
| Muscle relaxant, n (%) | 794 (40.7) | 122 (27.2) | <0.001 |
| Steroid, n (%) | 188 (9.6) | 24 (5.4) | 0.004 |
| Anti-platelet, n (%) | 69 (3.5) | 19 (4.2) | 0.476 |
| Anti-coagulant, n (%) | 1326 (68.0) | 358 (79.9) | <0.001 |
| Anti-hyperlipidemic, n (%) | 45 (2.3) | 20 (4.5) | 0.011 |
| Anti-Parkinson, n (%) | 6 (0.3) | 5 (1.1) | 0.022 |
| Antihistamine, n (%) | 826 (42.4) | 267 (59.6) | <0.001 |
| Genitourinary drug, n (%) | 2 (0.1) | 2 (0.4) | 0.108 |
| H2 blocker, n (%) | 474 (24.3) | 90 (20.1) | 0.058 |
| Preoperative hemoglobin (9.9–8/7.9–6/<6, g/dL), n (%) | 248(12.7)/10 (0.5)/0 (0) | 71(15.8)/3 (0.7)/0 (0) | 0.192 |
| Differences from normal levels of aspartate aminotransferase before surgery, units/L (median [IQR], maximum) | 0 ([0, 0], 282) | 0 ([0, 0], 422) | 0.895 |
| Differences from normal levels of alanine aminotransferase before surgery, units/L (median [IQR], maximum) | 0 ([0, 0], 303) | 0 ([0, 0], 654) | 0.274 |
| Preoperative hypoNa+/hyperNa+, n (%) | 224 (11.5)/7 (0.4) | 72 (16.1)/3 (0.7) | 0.018 |
| Preoperative hypoK+/hyperK+, n (%) | 195 (10.0)/4 (0.2) | 68 (15.2)/1 (0.2) | 0.007 |
| Differences from normal levels of uric acid before surgery, mg/dL (median [IQR], maximum) | 0 ([0, 0], 6.9) | 0 ([0, 0], 5.5) | 0.015 |
| Differences from normal levels of blood urea nitrogen before surgery, mg/dL (median [IQR], maximum) | 0 ([0, 0], 54.8) | 0 ([0, 0.1], 47.9) | 0.036 |
| Differences from normal levels of creatinine before surgery creatinine, mg/dL (median [IQR], maximum) | 0 ([0, 0], 9.0) | 0 ([0, 0], 5.1) | 0.086 |
| Preoperative hypoalbuminemia/hyperalbuminemia, n (%) | 948 (48.6)/1 (0.1) | 266 (59.4)/0 (0) | <0.001 |
| Intraoperative factors | |||
| Generalanesthesia, n (%) | 1343 (68.9) | 343 (76.6) | 0.001 |
| Surgical type (ORIF/Hemi-R/THA), n (%) | 966(49.5)/759 (38.9)/225 (11.5) | 217(48.4)/210 (46.9)/21 (4.7) | <0.001 |
| Operation time, hour (median [IQR], maximum) | 1.2 ([1, 1.7], 8.4) | 1.2 ([0.9, 1.5], 4) | 0.007 |
| Intraoperative packed red blood cell, pack (median [IQR], maximum) | 0 ([0, 1], 10) | 1 ([0, 1], 6) | 0.003 |
| Intraoperative fresh frozen plasma, pack (median [IQR], maximum) | 0 ([0, 0], 6) | 0 ([0, 0], 3) | 0.043 |
| Intraoperative platelet concentration, pack (median [IQR], maximum) | 0 ([0, 0], 10) | 0 ([0, 0], 10) | 0.357 |
| Opioid use, n (%) | 967 (49.6) | 268 (59.8) | <0.001 |
| Midazolam, mg (median [IQR], maximum) | 0 ([0, 0], 15) | 0 ([0, 0], 5) | <0.001 |
| Oliguria (<0.5 mL/kg/hour), n (%) | 577 (29.6) | 120 (26.8) | 0.239 |
| Administered fluid, L (median [IQR], maximum) | 1 ([0.8, 1.4], 6.3) | 1 ([0.8, 1.3], 3.7) | 0.301 |
| Estimated blood loss, L (median [IQR], maximum) | 0.5 ([0.2, 0.5], 10) | 0.5 ([0.2, 0.5], 2.5) | 0.269 |
| Postoperative factors | |||
| Postoperative packed red blood cell, pack/day (median [IQR], maximum) | 0 ([0, 0.3], 1.6) | 0 ([0, 0.3], 6) | 0.901 |
| Postoperative fresh frozen plasma, pack/day (median [IQR], maximum) | 0 ([0, 0], 0.7) | 0 ([0, 0], 4) | 0.042 |
| Postoperative platelet concentration, pack/day (median [IQR], maximum) | 0 ([0, 0], 4.3) | 0 ([0, 0], 5) | 0.04 |
| Postoperative hemoglobin (9.9–8/7.9–6/<6, g/dL), n (%), g/dL (median [IQR], maximum) | 379 (19.4)/24 (1.2)/2 (0.1) | 94 (21.0)/9 (2.0)/1 (0.2) | 0.433 |
| Differences from normal levels of postoperative aspartate aminotransferase, units/L (median [IQR], maximum) | 0 ([0, 0], 2475) | 0 ([0, 0], 178) | 0.29 |
| Differences from normal levels of postoperative alanine aminotransferase, units/L (median [IQR], maximum) | 0 ([0, 0], 1401) | 0 ([0, 0], 71) | 0.289 |
| Postoperative hypoNa+/hyperNa+, mEq/L (median [IQR], maximum) | 248 (12.7)/22 (1.1) | 84 (18.8)/6 (1.3) | 0.003 |
| Postoperative hypoK+/hyperK+, mmol/L (median [IQR], maximum) | 234 (12.0)/12 (0.6) | 80 (17.9)/4 (0.9) | 0.003 |
| Differences from normal levels of postoperative uric acid, mg/dL (median [IQR], maximum) | 0 ([0, 0], 3.9) | 0 ([0, 0], 3.8) | 0.451 |
| Differences from normal levels of postoperative blood urea nitrogen, mg/dL (median [IQR], maximum) | 0 ([0, 0], 48.1) | 0 ([0, 0], 58.3) | 0.014 |
| Differences from normal levels of postoperative creatinine, mg/dL (median [IQR], maximum) | 0.7 (0.6, 0.9) | 0.7 (0.6, 0.9) | 0.212 |
| Postoperative albumin, g/dL (median [IQR], maximum) | 1866 (95.7)/0 (0) | 442 (98.7)/0 (0) | 0.003 |
| Differences from normal levels in postoperative maximum body temperature, °C (median [IQR], maximum) | 0.7 ([0.3, 1.1], 3) | 0.7 ([0.3, 1.1], 2.5) | 0.455 |
| Differences from normal levels of postoperative erythrocyte sedimentation rate, mm/hr (median [IQR], maximum) | 30 ([15, 48], 104) | 15 ([2, 32], 104) | <0.001 |
| Differences from normal levels of postoperative C-reactive protein, mg/L (median [IQR], maximum) | 0 ([0, 0], 8.2) | 0 ([0, 0], 8.7) | 0.244 |
| Intensive care unit, n (%) | 255 (13.1) | 114 (25.4) | <0.001 |
| Patient-controlled analgesia, n (%) | 1906 (97.7) | 442 (98.7) | 0.221 |
IQR, interquartile range; ASA, American Society of Anesthesiologists; hypoNa+, hyponatremia; hyperNa+, hypernatremia; hypoK+, hypokalemia; hyperK+, hyperkalemia; ORIF, open reduction and internal fixation; Hemi-R, hemiarthroplasty; THA, total hip arthroplasty.
Table 2.
Intraoperative and postoperative red blood cell transfusion distributions.
| Intraoperative RBC Transfusion, Pack | Postoperative RBC Transfusion, Pack | ||||
|---|---|---|---|---|---|
| Pack | No Delirium, n (%) | Delirium, n (%) | Percentile | No Delirium, Pack/Day | Delirium, Pack/Day |
| 0 | 1140(58.5) | 222 (49.6) | 10 | 0 | 0 |
| 1 | 375 (19.2) | 116 (25.9) | 20 | 0 | 0 |
| 2 | 337 (17.3) | 80 (17.9) | 30 | 0 | 0 |
| 3 | 66 (3.4) | 24 (5.4) | 40 | 0 | 0 |
| 4 | 19 (1.0) | 4 (0.9) | 50 | 0 | 0 |
| 5 | 6 (0.3) | 1 (0.2) | 60 | 0.1 | 0 |
| 6 | 2 (0.1) | 1 (0.2) | 70 | 0.3 | 0.3 |
| 7 | 1 (0.1) | 0 (0.0) | 80 | 0.3 | 0.5 |
| 8 | 3 (0.2) | 0 (0.0) | 90 | 0.3 | 0.8 |
| 9 | 0 (0.0) | 0 (0.0) | |||
| 10 | 1 (0.1) | 0 (0.0) | |||
RBC, red blood cell.
Table 3.
The odds ratio of intraoperative and postoperative red blood cell transfusion (pack) for developing postoperative delirium.
Table 3.
The odds ratio of intraoperative and postoperative red blood cell transfusion (pack) for developing postoperative delirium.
| Odds Ratio [95% Confidence Interval] | p-Value | ||
|---|---|---|---|
| Intraoperative packed red blood cell, pack | Unadjusted | 0.94 [0.86–1.02] | 0.143 |
| Adjusted | 1.02 [0.9–1.17] | 0.751 | |
| Postoperative packed red blood cell, pack/day | Unadjusted | 1.28 [1.04–1.57] | 0.022 |
| Adjusted | 2.53 [1.88–3.41] | <0.001 |
Table 4.
The odds ratios of preoperative, intraoperative, and postoperative risk factors for developing postoperative delirium.
Table 4.
The odds ratios of preoperative, intraoperative, and postoperative risk factors for developing postoperative delirium.
| Hazard Ratio (95% Confidence Interval) | p-Value | |
|---|---|---|
| Preoperative Factors | ||
| Age, year | 1.05 (1.04 to 1.07) | <0.001 |
| Male | 1.16 (0.9 to 1.5) | 0.26 |
| Obesity (Body mass index > 29.9) | 0.37 (0.14 to 1.01) | 0.05 |
| American Society of Anesthesiologists physical status >2 | 1.84 (1.4 to 2.42) | <0.001 |
| Emergency surgery | 1.02 (0.79 to 1.32) | 0.86 |
| Hypertension | 0.98 (0.79 to 1.21) | 0.86 |
| Diabetes | 1.34 (1.08 to 1.67) | 0.01 |
| Stroke | 1.13 (0.87 to 1.48) | 0.36 |
| Cancer | 1.15 (0.85 to 1.56) | 0.37 |
| Parkinson disease | 1.5 (0.94 to 2.39) | 0.09 |
| Dementia | 1.99 (1.53 to 2.6) | <0.001 |
| Depression | 1.05 (0.64 to 1.71) | 0.85 |
| Kidney disease | 0.89 (0.57 to 1.39) | 0.62 |
| Liver disease | 0.68 (0.4 to 1.16) | 0.16 |
| Insomnia | 1.13 (0.79 to 1.61) | 0.5 |
| Alcohol | 1.21 (0.84 to 1.76) | 0.31 |
| Smoking | 1.43 (0.98 to 2.1) | 0.06 |
| Calcium channel blocker | 1.05 (0.85 to 1.29) | 0.68 |
| Diuretics | 0.9 (0.63 to 1.28) | 0.55 |
| Beta blocker | 0.71 (0.47 to 1.07) | 0.1 |
| Angiotensin converting enzyme inhibitors | 0.68 (0.25 to 1.82) | 0.44 |
| Angiotensin receptor blockers | 1.25 (0.85 to 1.85) | 0.26 |
| Miscellaneous drug | 0.65 (0.41 to 1.03) | 0.07 |
| Anti-depressant | 0.84 (0.4 to 1.77) | 0.65 |
| Hypnotics | 0.71 (0.55 to 0.91) | 0.01 |
| Anti-psychotics | 1.29 (0.95 to 1.76) | 0.11 |
| Opioid | 0.58 (0.22 to 1.5) | 0.26 |
| Non-steroid alanti-inflammatorydrug | 0.74 (0.58 to 0.94) | 0.01 |
| Analgesic except non-steroidalanti-inflammatorydrug | 1.63 (0.8 to 3.29) | 0.18 |
| Muscle relaxant | 0.75 (0.59 to 0.95) | 0.02 |
| Steroid | 0.53 (0.34 to 0.82) | <0.001 |
| Anti-platelet | 0.93 (0.55 to 1.58) | 0.8 |
| Anti-coagulant | 1.07 (0.81 to 1.43) | 0.62 |
| Anti-hyperlipidemic | 1.34 (0.81 to 2.22) | 0.26 |
| Anti-Parkinson | 1.22 (0.43 to 3.44) | 0.71 |
| Antihistamine | 1.53 (1.19 to 1.96) | <0.001 |
| Genitourinary drug | 1.18 (0.26 to 5.4) | 0.83 |
| H2 blocker | 0.9 (0.69 to 1.18) | 0.45 |
| Preoperative hemoglobin | ||
| 9.9–8 g/dL | 0.86 (0.64 to 1.16) | 0.32 |
| 7.9–6 g/dL | 0.8 (0.23 to 2.84) | 0.73 |
| Differences from normal levels of aspartate aminotransferase before surgery, units/L | 1.0 (0.99 to 1.02) | 0.92 |
| Differences from normal levels of alanine aminotransferase before surgery, units/L | 1.01 (1.0 to 1.02) | 0.19 |
| Preoperative Sodium | ||
| Hyponatremia | 0.95 (0.71 to 1.27) | 0.73 |
| Hypernatremia | 1.14 (0.3 to 4.43) | 0.85 |
| Preoperative Potassium | ||
| Hypokalemia | 1.3 (0.96 to 1.76) | 0.09 |
| Hyperkalemia | 1.07 (0.14 to 7.9) | 0.95 |
| Differences from normal levels of uric acid before surgery, mg/dL | 1.17 (0.92 to 1.5) | 0.2 |
| Differences from normal levels of blood urea nitrogen before surgery, mg/dL | 1.0 (0.97 to 1.03) | 0.83 |
| Differences from normal levels of creatinine before surgery creatinine, mg/dL | 0.75 (0.45 to 1.26) | 0.28 |
| Preoperative Hypoalbuminemia | 0.94 (0.76 to 1.17) | 0.59 |
| Intraoperativefactors | ||
| Generalanesthesia | 0.92 (0.69 to 1.22) | 0.55 |
| Surgical type (reference: ORIF) | ||
| Hemiarthroplasty | 0.97 (0.78 to 1.22) | 0.81 |
| Totalarthroplasty | 0.97 (0.59 to 1.59) | 0.9 |
| Operation time, hour | 1.01 (0.81 to 1.26) | 0.93 |
| Intraoperative fresh frozen plasma, pack | 0.87 (0.51 to 1.48) | 0.6 |
| Intraoperative platelet concentration, pack | 1.11 (0.93 to 1.31) | 0.24 |
| Opioid use | 1.04 (0.82 to 1.32) | 0.75 |
| Midazolam, mg | 1.01 (0.85 to 1.2) | 0.9 |
| Oliguria (<0.5 mL/kg/hour) | 1.03 (0.81 to 1.31) | 0.8 |
| Administered fluid, L | 0.91 (0.68 to 1.22) | 0.54 |
| Estimated blood loss, L | 0.96 (0.62 to 1.5) | 0.87 |
| Postoperative factors | ||
| Postoperative fresh frozen plasma, pack/day | 0.39 (0.2 to 0.77) | 0.01 |
| Postoperative platelet concentration, pack/day | 0.77 (0.51 to 1.18) | 0.23 |
| Postoperative hemoglobin | ||
| 9.9–8 g/dL | 0.83 (0.64 to 1.07) | 0.15 |
| 7.9–6 g/dL | 0.93 (0.45 to 1.93) | 0.86 |
| <6 g/dL | 1.48 (0.18 to 12.17) | 0.71 |
| Differences from normal levels of postoperative aspartate aminotransferase, units/L | 1.01 (1.0 to 1.02) | 0.32 |
| Differences from normal levels of postoperative alanine aminotransferase, units/L | 0.96 (0.91 to 1.02) | 0.21 |
| Postoperative sodium | ||
| Hyponatremia | 1.08 (0.81 to 1.43) | 0.61 |
| Hypernatremia | 1.29 (0.56 to 2.99) | 0.55 |
| Postoperative potassium | ||
| Hyponatremia | 1.13 (0.85 to 1.5) | 0.41 |
| Hypernatremia | 1.48 (0.48 to 4.51) | 0.5 |
| Differences from normal levels of postoperative uric acid, mg/dL | 0.96 (0.56 to 1.63) | 0.87 |
| Differences from normal levels of postoperative blood urea nitrogen, mg/dL | 1.0 (0.97 to 1.03) | 0.96 |
| Differences from normal levels of postoperative creatinine, mg/dL | 1.27 (0.85 to 1.9) | 0.24 |
| Postoperativehypoalbuminemia | 0.86 (0.37 to 2.02) | 0.74 |
| Differences from normal level in postoperative maximum body temperature, °C | 0.92 (0.75 to 1.14) | 0.46 |
| Differences from normal levels of postoperative erythrocyte sedimentation rate, mm/h | 0.97 (0.97 to 0.98) | <0.001 |
| Differences from normal levels of postoperative C-reactive protein, mg/L | 1.0 (1.0 to 1.0) | 0.25 |
| Intensive care unit | 1.31 (1.02 to 1.68) | 0.03 |
| Patient-controlled analgesia | 0.95 (0.4 to 2.25) | 0.91 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Lee, S.-S.; Kim, J.-H.; Lee, J.-J.; Kwon, Y.-S.; Seo, E.-M. The Impact of Blood Transfusion in Developing Postoperative Delirium in Patients with Hip Fracture Surgery. J. Clin. Med. 2023, 12, 4696. https://doi.org/10.3390/jcm12144696
AMA Style
Lee S-S, Kim J-H, Lee J-J, Kwon Y-S, Seo E-M. The Impact of Blood Transfusion in Developing Postoperative Delirium in Patients with Hip Fracture Surgery. Journal of Clinical Medicine. 2023; 12(14):4696. https://doi.org/10.3390/jcm12144696
Chicago/Turabian StyleLee, Sang-Soo, Jong-Ho Kim, Jae-Jun Lee, Young-Suk Kwon, and Eun-Min Seo. 2023. "The Impact of Blood Transfusion in Developing Postoperative Delirium in Patients with Hip Fracture Surgery" Journal of Clinical Medicine 12, no. 14: 4696. https://doi.org/10.3390/jcm12144696
APA StyleLee, S. -S., Kim, J. -H., Lee, J. -J., Kwon, Y. -S., & Seo, E. -M. (2023). The Impact of Blood Transfusion in Developing Postoperative Delirium in Patients with Hip Fracture Surgery. Journal of Clinical Medicine, 12(14), 4696. https://doi.org/10.3390/jcm12144696
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
